117 related articles for article (PubMed ID: 37087801)
1. Selamectin increases cisplatin sensitivity by inhibiting cisplatin-resistant genes expression and autophagy in uveal melanoma.
He J; Chen J; Shen J
Biochem Biophys Res Commun; 2023 Jun; 661():75-81. PubMed ID: 37087801
[TBL] [Abstract][Full Text] [Related]
2. Electrochemotherapy with bleomycin and cisplatin enhances cytotoxicity in primary and metastatic uveal melanoma cell lines in vitro.
Fiorentzis M; Kalirai H; Katopodis P; Seitz B; Viestenz A; Coupland SE
Neoplasma; 2018; 65(2):210-215. PubMed ID: 29534581
[TBL] [Abstract][Full Text] [Related]
3. Proteomics analysis: inhibiting the expression of P62 protein by chloroquine combined with dacarbazine can reduce the malignant progression of uveal melanoma.
Fei X; Xie X; Qin R; Wang A; Meng X; Sun F; Zhao Y; Jiang D; Chen H; Huang Q; Ji X; Wang Z
BMC Cancer; 2022 Apr; 22(1):408. PubMed ID: 35421957
[TBL] [Abstract][Full Text] [Related]
4.
Li P; He J; Yang Z; Ge S; Zhang H; Zhong Q; Fan X
Autophagy; 2020 Jul; 16(7):1186-1199. PubMed ID: 31462126
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of survivin expression enhances sensitivity of cultured uveal melanoma cells to cisplatin treatment.
Li H; Niederkorn JY; Neelam S; Alizadeh H
Exp Eye Res; 2006 Jul; 83(1):176-82. PubMed ID: 16584731
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy of VP22-CD/5-FC suicide gene system mediated by lentivirus in a murine uveal melanoma model.
Liu S; Song W; Liu F; Zhang J; Zhu S
Exp Eye Res; 2018 Jul; 172():144-151. PubMed ID: 29660328
[TBL] [Abstract][Full Text] [Related]
8. ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells.
Kaochar S; Dong J; Torres M; Rajapakshe K; Nikolos F; Davis CM; Ehli EA; Coarfa C; Mitsiades N; Poulaki V
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):132-143. PubMed ID: 29332125
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of microRNA-130a represses uveal melanoma cell migration and invasion through inactivation of the Wnt/β-catenin signaling pathway by downregulating USP6.
Wu S; Han M; Zhang C
Cancer Gene Ther; 2022 Jul; 29(7):930-939. PubMed ID: 34522027
[TBL] [Abstract][Full Text] [Related]
10. Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin.
Bérubé M; Talbot M; Collin C; Paquet-Bouchard C; Germain L; Guérin SL; Petitclerc E
Int J Oncol; 2005 Feb; 26(2):405-13. PubMed ID: 15645125
[TBL] [Abstract][Full Text] [Related]
11. Immune implication of an autophagy-related prognostic signature in uveal melanoma.
Chuah S; Chew V
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34374416
[TBL] [Abstract][Full Text] [Related]
12. Resistance of uveal melanoma to the interstrand cross-linking agent mitomycin C is associated with reduced expression of CYP450R.
Gravells P; Hoh L; Canovas D; Rennie IG; Sisley K; Bryant HE
Br J Cancer; 2011 Mar; 104(7):1098-105. PubMed ID: 21386838
[TBL] [Abstract][Full Text] [Related]
13. The role of RASSF1A in uveal melanoma.
Dratviman-Storobinsky O; Cohen Y; Frenkel S; Merhavi-Shoham E; El SD; Binkovsky N; Pe'er J; Goldenberg-Cohen N
Invest Ophthalmol Vis Sci; 2012 Oct; 53(6):2611-9. PubMed ID: 22447862
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-145 suppresses uveal melanoma angiogenesis and growth by targeting neuroblastoma RAS viral oncogene homolog and vascular endothelial growth factor.
Yang JY; Li Y; Wang Q; Zhou WJ; Yan YN; Wei WB
Chin Med J (Engl); 2020 Aug; 133(16):1922-1929. PubMed ID: 32826455
[TBL] [Abstract][Full Text] [Related]
15. Monensin synergizes with chemotherapy in uveal melanoma through suppressing RhoA.
Zeng C; Long M; Lu Y
Immunopharmacol Immunotoxicol; 2023 Feb; 45(1):35-42. PubMed ID: 36043455
[TBL] [Abstract][Full Text] [Related]
16. An autophagy-related prognostic signature associated with immune microenvironment features of uveal melanoma.
Zheng Z; Zhang L; Tu Z; Deng Y; Yin X
Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33682883
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH
Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716
[TBL] [Abstract][Full Text] [Related]
18. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).
Oláh G; Dobos N; Vámosi G; Szabó Z; Sipos É; Fodor K; Harda K; Schally AV; Halmos G
Eur J Pharm Sci; 2018 Oct; 123():371-376. PubMed ID: 30076951
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.
Decaudin D; Frisch Dit Leitz E; Nemati F; Tarin M; Naguez A; Zerara M; Marande B; Vivet-Noguer R; Halilovic E; Fabre C; Jochemsen A; Roman-Roman S; Alsafadi S
Eur J Cancer; 2020 Feb; 126():93-103. PubMed ID: 31927215
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of DNA-PKcs activity re-sensitizes uveal melanoma cells to radio- and chemotherapy.
Zhang B; Wu H; Hao J; Wu Y; Yang B
Biochem Biophys Res Commun; 2020 Feb; 522(3):639-646. PubMed ID: 31785810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
